Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Goodwill Goodwill & Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Castle Biosciences (CSTL) Intangibles (2018 - 2022)

Castle Biosciences' Intangibles history spans 3 years, with the latest figure at $87.3 million for Q1 2022.

On a quarterly basis, Intangibles changed N/A to $87.3 million in Q1 2022 year-over-year; TTM through Mar 2022 was $87.3 million, a N/A change, with the full-year FY2021 number at $88.9 million, changed N/A from a year prior.
Intangibles hit $87.3 million in Q1 2022 for Castle Biosciences, down from $88.9 million in the prior quarter.
Over the last five years, Intangibles for CSTL hit a ceiling of $88.9 million in Q4 2021 and a floor of $4000.0 in Q4 2018.
Historically, Intangibles has averaged $48.2 million across 3 years, with a median of $32.8 million in 2021.